ArticleRheumatology and therapy2026
Validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in a Chinese Cohort: Comparison with SLEDAI-2-K.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated multi-omics profiling identifies aging-related molecular signatures and convergent interferon signaling in systemic lupus erythematosus.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionAccurate assessment of disease activity in systemic lupus erythematosus (SLE) remains a persistent challenge. We aimed to validate the SLE disease activity score (SLE-DAS) in Chinese patients.
methodsWe analyzed the agreement between SLE-DAS and SLEDAI-2 K using our prospective STAR cohort. Construct validity was assessed through correlations with physician global assessment (PGA), as well as through known-group discrimination (PGA-cut off ≥ 1 for active). Factors associated with classification discordance and the association between baseline SLE-DAS and 12-month organ damage accrual were assessed using logistic regression.
resultsAmong 507 SLE patients, SLE-DAS demonstrated strong correlations with PGA (r = 0.726, P < 0.001) and SLEDAI-2 K (r = 0.750, P < 0.001), with an overall agreement of 83.0% between SLE-DAS and SLEDAI-2 K. Both instruments demonstrated comparable discriminative power for active disease (SLE-DAS AUC = 0.832; SLEDAI-2 K AUC = 0.860). Among 211 patients with mild disease activity classified by SLEDAI-2 K, 61 were reclassified into higher categories by SLE-DAS. These patients exhibited higher PGA (0.8 ± 1.0 vs. 0.3 ± 0.7; P < 0.001) and glucocorticoid doses (25.7 ± 22.3 vs. 11.3 ± 15.5; P < 0.001) than those with concordant classifications. Lupus nephritis (45.9% vs. 18.0%; P < 0.001) and hematological involvement (32.8% vs. 18.0%; P = 0.020) were more frequent in them. We identified that nephritis (OR = 4.57, 95% CI 2.18-9.57, P < 0.001) and hematological involvement (OR = 2.76, 95% CI 1.27-6.02, P = 0.011) were associated with classification discordance. Baseline SLE-DAS was positively associated with SLE SLICC/ACR Damage Index (SDI) accrual at 12 months of follow-up (OR = 1.38, P = 0.038).
conclusionsSLE-DAS demonstrates superior accuracy in assessing disease activity compared to SLEDAI-2 K, likely attributable to refinements in assessing nephritis and hematological manifestations. Baseline SLE-DAS also exhibited a positive association with short-term organ damage accrual, though long-term validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.